Your browser doesn't support javascript.
loading
Cyclophilin A is a ligand for RAGE in thrombo-inflammation.
Seizer, Peter; von Ungern-Sternberg, Saskia N I; Haug, Verena; Dicenta, Valerie; Rosa, Annabelle; Butt, Elke; Nöthel, Moritz; Rohlfing, Anne-Katrin; Sigle, Manuel; Nawroth, Peter P; Nussbaum, Claudia; Sperandio, Markus; Kusch, Charly; Meub, Mara; Sauer, Markus; Münzer, Patrick; Bieber, Kristin; Stanger, Anna; Mack, Andreas F; Huber, René; Brand, Korbinian; Lehners, Moritz; Feil, Robert; Poso, Antti; Krutzke, Konstantin; Schäffer, Tilman E; Nieswandt, Bernhard; Borst, Oliver; May, Andreas E; Zernecke, Alma; Gawaz, Meinrad; Heinzmann, David.
Affiliation
  • Seizer P; Department of Cardiology and Angiology, Universitätsklinikum Tübingen, Eberhard Karls University Tübingen, Otfried-Müller-Str. 10, 72076 Tübingen, Germany.
  • von Ungern-Sternberg SNI; Department of Cardiology and Angiology, Ostalbklinikum Aalen, Aalen, Germany.
  • Haug V; Department of Cardiology and Angiology, Universitätsklinikum Tübingen, Eberhard Karls University Tübingen, Otfried-Müller-Str. 10, 72076 Tübingen, Germany.
  • Dicenta V; Department of Cardiology and Angiology, Universitätsklinikum Tübingen, Eberhard Karls University Tübingen, Otfried-Müller-Str. 10, 72076 Tübingen, Germany.
  • Rosa A; Department of Cardiology and Angiology, Universitätsklinikum Tübingen, Eberhard Karls University Tübingen, Otfried-Müller-Str. 10, 72076 Tübingen, Germany.
  • Butt E; Institute of Experimental Biomedicine, University Hospital Würzburg, Würzburg, Germany.
  • Nöthel M; Institute of Experimental Biomedicine, University Hospital Würzburg, Würzburg, Germany.
  • Rohlfing AK; Department of Internal Medicine II, Cardiology, Pneumology, Angiology, University Hospital Bonn, Bonn, Germany.
  • Sigle M; Department of Cardiology and Angiology, Universitätsklinikum Tübingen, Eberhard Karls University Tübingen, Otfried-Müller-Str. 10, 72076 Tübingen, Germany.
  • Nawroth PP; Department of Cardiology and Angiology, Universitätsklinikum Tübingen, Eberhard Karls University Tübingen, Otfried-Müller-Str. 10, 72076 Tübingen, Germany.
  • Nussbaum C; Department of Internal Medicine 1 and Clinical Chemistry, University Hospital of Heidelberg, Heidelberg, Germany.
  • Sperandio M; German Center for Diabetes Research (DZD), Munich-Neuherberg, Germany.
  • Kusch C; Joint Heidelberg-ICD Translational Diabetes Program, Helmholtz-Zentrum, Munich, Germany.
  • Meub M; Division of Neonatology, Department of Pediatrics, Dr. von Hauner Children's Hospital, LMU University Hospital, LMU Munich, Munich, Germany.
  • Sauer M; Institute of Cardiovascular Physiology and Pathophysiology, Ludwig-Maximilians University Munich, Munich, Germany.
  • Münzer P; German Centre for Cardiovascular Research (Deutsches Zentrum für Herz-Kreislauf-Forschung, DZHK), Munich Heart Alliance Partner Site, Munich, Germany.
  • Bieber K; Institute of Experimental Biomedicine, University Hospital Würzburg, Würzburg, Germany.
  • Stanger A; Department of Biotechnology und Biophysics, Julius-Maximilians University, Würzburg, Germany.
  • Mack AF; Department of Biotechnology und Biophysics, Julius-Maximilians University, Würzburg, Germany.
  • Huber R; Department of Cardiology and Angiology, Universitätsklinikum Tübingen, Eberhard Karls University Tübingen, Otfried-Müller-Str. 10, 72076 Tübingen, Germany.
  • Brand K; DFG Heisenberg Group Cardiovascular Thromboinflammation and Translational Thrombocardiology, University of Tübingen, Tübingen, Germany.
  • Lehners M; Department of Hematology, Oncology, Immunology und Pulmonology, Universitätsklinikum Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany.
  • Feil R; Department of Hematology, Oncology, Immunology und Pulmonology, Universitätsklinikum Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany.
  • Poso A; Institute of Clinical Anatomy and Cell Analytics, Eberhard Karls University Tübingen, Tübingen, Germany.
  • Krutzke K; Institute of Clinical Chemistry, Hannover Medical School, Hannover, Germany.
  • Schäffer TE; Institute of Clinical Chemistry, Hannover Medical School, Hannover, Germany.
  • Nieswandt B; Interfakultäres Institut für Biochemie, Eberhard Karls University Tübingen, Tübingen, Germany.
  • Borst O; Interfakultäres Institut für Biochemie, Eberhard Karls University Tübingen, Tübingen, Germany.
  • May AE; Department of Internal Medicine VIII, University Hospital of Tübingen, Tübingen, Germany.
  • Zernecke A; School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.
  • Gawaz M; Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls University Tübingen, Tübingen, Germany.
  • Heinzmann D; Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls University, Tübingen, Germany.
Cardiovasc Res ; 120(4): 385-402, 2024 Mar 30.
Article in En | MEDLINE | ID: mdl-38175781
ABSTRACT

AIMS:

Cyclophilin A (CyPA) induces leucocyte recruitment and platelet activation upon release into the extracellular space. Extracellular CyPA therefore plays a critical role in immuno-inflammatory responses in tissue injury and thrombosis upon platelet activation. To date, CD147 (EMMPRIN) has been described as the primary receptor mediating extracellular effects of CyPA in platelets and leucocytes. The receptor for advanced glycation end products (RAGE) shares inflammatory and prothrombotic properties and has also been found to have similar ligands as CD147. In this study, we investigated the role of RAGE as a previously unknown interaction partner for CyPA. METHODS AND

RESULTS:

Confocal imaging, proximity ligation, co-immunoprecipitation, and atomic force microscopy were performed and demonstrated an interaction of CyPA with RAGE on the cell surface. Static and dynamic cell adhesion and chemotaxis assays towards extracellular CyPA using human leucocytes and leucocytes from RAGE-deficient Ager-/- mice were conducted. Inhibition of RAGE abrogated CyPA-induced effects on leucocyte adhesion and chemotaxis in vitro. Accordingly, Ager-/- mice showed reduced leucocyte recruitment and endothelial adhesion towards CyPA in vivo. In wild-type mice, we observed a downregulation of RAGE on leucocytes when endogenous extracellular CyPA was reduced. We furthermore evaluated the role of RAGE for platelet activation and thrombus formation upon CyPA stimulation. CyPA-induced activation of platelets was found to be dependent on RAGE, as inhibition of RAGE, as well as platelets from Ager-/- mice showed a diminished activation and thrombus formation upon CyPA stimulation. CyPA-induced signalling through RAGE was found to involve central signalling pathways including the adaptor protein MyD88, intracellular Ca2+ signalling, and NF-κB activation.

CONCLUSION:

We propose RAGE as a hitherto unknown receptor for CyPA mediating leucocyte as well as platelet activation. The CyPA-RAGE interaction thus represents a novel mechanism in thrombo-inflammation.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thrombosis / Cyclophilin A Limits: Animals / Humans Language: En Journal: Cardiovasc Res Year: 2024 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thrombosis / Cyclophilin A Limits: Animals / Humans Language: En Journal: Cardiovasc Res Year: 2024 Document type: Article Affiliation country: